Edesa Biotech: Up on FDA nod for study on potential COVID-19 drug
19/10/2020 15:48
** Drug developer's shares EDSA.O rise as much as 30%
before settling to trade up 4% at $8
** EDSA gets U.S. FDA clearance to start the Phase 2 portion
of its mid-to-late stage study testing its experimental drug,
EB05, in hospitalized COVID-19 patients urn:newsml:reuters.com:*:nACS6sRtPa
** Co says EB05 is an antibody that could help regulate the
overactive immune response associated with Acute Respiratory
Distress Syndrome (ARDS) – the leading cause of death in
COVID-19 patients
** EDSA has already received Health Canada approval to begin
late-stage clinical study of drug urn:newsml:reuters.com:*:nL4N2DS3DS
** More than 1.4 mln shares traded, 11 times their 25-day
moving average
** Up to Friday's close, stock up 87.8% YTD
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))